vVardis Files for an IPO. Dental Innovation Is Getting a Public-Market Benchmark.

vVardis has filed for a U.S. initial public offering, giving the dental industry an unusually detailed look at the economics behind a rapidly growing clinical dental company.

The Switzerland-based company reported $28.6 million in revenue for the first six months of 2026, up from $9.1 million in the same period last year. Its net loss narrowed from $32.1 million to $27.8 million.

vVardis plans to list on the New York Stock Exchange under the ticker VVVV. Goldman Sachs, J.P. Morgan, William Blair, UBS Investment Bank, Deutsche Bank Securities and Apollo Global Securities are among the underwriters.

Those numbers make this an important financing event.

But the more interesting dental story is what vVardis has built underneath them.

The company, founded by dentists and sisters Haley Abivardi and Goly Abivardi, develops non-invasive treatments for early-stage cavities. That means the core value proposition is not administrative software around dentistry. It sits directly in the clinical treatment pathway.

Explore the broader dental technology market map on Avized.

More Than 20,000 U.S. Practices Is the Number to Watch

As of June 30, vVardis said its products had been sold to more than 20,000 of the roughly 110,000 general dental practices in the United States.

That is roughly one in five general dental practices.

For any dental company, that level of practice penetration is strategically important.

Dental remains a highly fragmented market. Reaching thousands of independent practices requires more than a compelling product. It requires repeatable clinical education, sales execution, distribution and enough workflow value for dentists to adopt something new.

The bigger opportunity is what happens once a clinical product becomes part of how dentists think about a disease state.

That is when a company can begin moving from selling a product to establishing a category.

The Revenue Growth Is Real. So Are the Losses.

The IPO filing provides an important look at the economics of building that category.

Revenue increased from $9.1 million to $28.6 million in the first half of the year.

But vVardis still recorded a $27.8 million net loss during the same six-month period.

That is a substantial gap.

The company is therefore approaching the public markets while still investing heavily in growth. vVardis said it plans to use IPO proceeds for working capital, operating expenses and capital expenditures.

For investors, the question becomes less about whether vVardis can grow—the current trajectory clearly shows growth—and more about the eventual economics of that growth.

Can the company continue expanding practice penetration while sales and education costs become more efficient?

Can existing practices increase utilization after adoption?

Can the company deepen its relationship with an installed base already measured in the tens of thousands of practices?

Those are the questions that determine whether a rapidly growing dental product becomes a durable dental platform.

Heartland's Presence Is Particularly Interesting

The investor list is notable for the dental market.

vVardis counts OrbiMed, Heartland Dental and affiliates of Apollo Global Management among its backers.

Heartland is especially interesting because large DSOs can represent more than capital.

Large dental groups increasingly function as distribution infrastructure for innovation.

A new clinical technology can potentially be introduced across many supported practices, dentists and patients through a single strategic relationship rather than winning thousands of offices individually.

The same dynamic is becoming increasingly important across dental AI, scanners, implants, aligners, RCM technology and other categories.

For emerging vendors, DSO relationships can therefore influence product adoption, evidence generation and commercial scale at the same time.

Dental Has Very Few Public-Market Comparables

Another reason the filing matters: dental technology has relatively few clean public-market benchmarks.

The industry contains hundreds of private software companies, clinical technology businesses, equipment manufacturers and services companies. Far fewer reach the public markets as independent dental businesses.

That makes vVardis useful even for companies that have nothing to do with early-stage cavity treatment.

If the offering proceeds, public investors will begin assigning a market value to factors such as:

• revenue growth,
• practice penetration,
• clinical adoption,
• operating losses,
• sales efficiency,
• intellectual property,
• and the size of the underlying treatment opportunity.

Private dental companies and their investors will inevitably watch those metrics.

That makes VVVV a potential public-market reference point for the broader dental innovation market.

Clinical Technology Has a Different Kind of Leverage

Much of modern dental technology sits around the treatment itself.

Software can help practices diagnose, document, schedule, finance, bill, communicate and analyze.

vVardis is different because its product sits in the clinical intervention itself.

That can create a different type of leverage.

If dentists adopt a new treatment approach broadly, growth does not necessarily depend only on replacing an existing vendor. The company can potentially expand the number of situations in which clinicians actively intervene.

That is what makes clinical category creation so powerful.

The addressable market can grow as the treatment behavior changes.

The Public Markets Will Test the Story

Reuters notes that the U.S. IPO market remains selective, with investors scrutinizing valuations more closely even after a strong start to the year. Healthcare and pharmaceutical companies, however, have remained relatively insulated from broader macroeconomic uncertainty.

That makes the timing useful.

Private capital can finance a compelling vision.

Public markets eventually demand repeatable economics.

For vVardis, the IPO process will test whether investors believe rapid revenue growth, broad practice penetration and a differentiated clinical treatment model can justify continued investment despite substantial current losses.

The final size and valuation of the offering have not yet been established.

But the company has already crossed an important threshold.

Dental now has a clinical technology company with products sold into more than 20,000 U.S. general dental practices, rapidly growing revenue and plans to trade directly on the NYSE.

Avized Take

The headline is that vVardis is going public.

The more important story is that a dental company built around a new clinical treatment approach has become large enough to attempt it.

That matters for the entire dental technology ecosystem.

Software companies often talk about changing workflows.

vVardis is attempting to change the clinical decision itself.

And the economics revealed through the IPO process will give the rest of the industry something it rarely gets:

a public-market benchmark for what dental category creation is worth.

The ticker VVVV may therefore become one of the more interesting dental metrics to watch—not just for investors, but for founders and operators building the next major dental technology company.

Related Avized research: Dental technology market map

Source: Reuters, October 9, 2026.